<?xml version="1.0" encoding="utf-8"?>
<rss version="2.0">
<channel>
<title>GATE Overflow for GATE BT - Recent activity in Immunology</title>
<link>https://bt.gateoverflow.in/activity/general-biology/immunology</link>
<description>Powered by Question2Answer</description>
<item>
<title>Edited: GATE BT 2026 | Question: 27</title>
<link>https://bt.gateoverflow.in/1294/gate-bt-2026-question-27?show=1294#q1294</link>
<description>&lt;p&gt;Match the immunological terms in $\textbf{Column I}$ with their function/description in the $\textbf{Column II}$&lt;/p&gt;&lt;p&gt;\[&lt;br&gt;\begin{array}{|l|l|}&lt;br&gt;\hline&lt;br&gt;\textbf{Column I} &amp;amp; \textbf{Column II} \\&lt;br&gt;\hline&lt;br&gt;\text{P. } J\ \text{gene} &amp;amp; 1.\ \text{Suppresses immune system by blocking calcineurin} \\&lt;br&gt;\hline&lt;br&gt;\text{Q. Cyclosporin} &amp;amp; 2.\ \text{Antibody binding site on a large molecule} \\&lt;br&gt;\hline&lt;br&gt;\text{R. Epitope} &amp;amp; 3.\ \text{Small foreign molecule which elicits an immune response only} \\&lt;br&gt;&amp;amp; \text{when combined with a carrier molecule} \\&lt;br&gt;\hline&lt;br&gt;\text{S. Hapten} &amp;amp; 4.\ \text{Contributes to antibody diversity} \\&lt;br&gt;\hline&lt;br&gt;\end{array}&lt;br&gt;\]&lt;/p&gt;&lt;ol start=&quot;1&quot; style=&quot;list-style-type: upper-alpha;&quot;&gt;&lt;li&gt;$\text{P-3; Q-4; R-2; S-1}$&lt;/li&gt;&lt;li&gt;$\text{P-2; Q-4; R-1; S-3}$&lt;/li&gt;&lt;li&gt;$\text{P-4; Q-1; R-2; S-3}$&lt;/li&gt;&lt;li&gt;$\text{P-1; Q-3; R-4; S-2}$&lt;/li&gt;&lt;/ol&gt;</description>
<category>Immunology</category>
<guid isPermaLink="true">https://bt.gateoverflow.in/1294/gate-bt-2026-question-27?show=1294#q1294</guid>
<pubDate>Tue, 17 Mar 2026 07:04:32 +0000</pubDate>
</item>
<item>
<title>Answered: GATE2014-20</title>
<link>https://bt.gateoverflow.in/231/gate2014-20?show=1018#a1018</link>
<description>innatee immunity</description>
<category>Immunology</category>
<guid isPermaLink="true">https://bt.gateoverflow.in/231/gate2014-20?show=1018#a1018</guid>
<pubDate>Thu, 07 Aug 2025 17:48:30 +0000</pubDate>
</item>
<item>
<title>Edited: GATE BT 2025 | Question: 29</title>
<link>https://bt.gateoverflow.in/1050/gate-bt-2025-question-29?show=1050#q1050</link>
<description>&lt;p&gt;​​​Correctly match the type of &lt;strong&gt;Hypersensitivity reaction &lt;/strong&gt;with its respective &lt;strong&gt;Example&lt;/strong&gt;.&lt;br&gt;
$$\begin{array}{|l|l|}&lt;br&gt;
\hline&amp;nbsp;\textbf{Hypersensitivity reaction} &amp;amp; \textbf{Example} \\&lt;br&gt;
\hline&amp;nbsp;\text{P. Type I} &amp;amp; 1.&amp;nbsp;\text{Tuberculin reaction} \\&lt;br&gt;
\hline&amp;nbsp;\text{Q. Type II}&amp;nbsp;&amp;amp; 2. \text{Arthus reaction} \\&lt;br&gt;
\hline&amp;nbsp;\text{R. Type III} &amp;amp; 3. \text{Chronic urticaria} \\&lt;br&gt;
\hline&amp;nbsp;\text{S. Type IV} &amp;amp; 4. \text{Systemic anaphylaxis} \\&lt;br&gt;
\hline&lt;br&gt;
\end{array}$$&lt;/p&gt;

&lt;ol start=&quot;1&quot; style=&quot;list-style-type:upper-alpha&quot;&gt;
	&lt;li&gt;$\mathrm{P}-3 ; \mathrm{Q}-4 ; \mathrm{R}-2 ; \mathrm{S}-1$&lt;/li&gt;
	&lt;li&gt;$\mathrm{P}-4 ; \mathrm{Q}-3 ; \mathrm{R}-1 ; \mathrm{S}-2$&lt;/li&gt;
	&lt;li&gt;$\mathrm{P}-4 ; \mathrm{Q}-3 ; \mathrm{R}-2 ; \mathrm{S}-1$&lt;/li&gt;
	&lt;li&gt;$\mathrm{P}-2 ; \mathrm{Q}-3 ; \mathrm{R}-4 ; \mathrm{S}-1$&lt;/li&gt;
&lt;/ol&gt;</description>
<category>Immunology</category>
<guid isPermaLink="true">https://bt.gateoverflow.in/1050/gate-bt-2025-question-29?show=1050#q1050</guid>
<pubDate>Mon, 02 Jun 2025 13:25:48 +0000</pubDate>
</item>
<item>
<title>Edited: GATE BT 2025 | Question: 5</title>
<link>https://bt.gateoverflow.in/1074/gate-bt-2025-question-5?show=1074#q1074</link>
<description>&lt;p&gt;​​​​​The diversity in $T$-cell receptors is generated by&lt;/p&gt;

&lt;ol start=&quot;1&quot; style=&quot;list-style-type:upper-alpha&quot;&gt;
	&lt;li&gt;gene rearrangements&lt;/li&gt;
	&lt;li&gt;somatic hypermutation of rearranged $V$ region&lt;/li&gt;
	&lt;li&gt;gene conversion&lt;/li&gt;
	&lt;li&gt;class switching&lt;/li&gt;
&lt;/ol&gt;</description>
<category>Immunology</category>
<guid isPermaLink="true">https://bt.gateoverflow.in/1074/gate-bt-2025-question-5?show=1074#q1074</guid>
<pubDate>Wed, 30 Apr 2025 19:34:11 +0000</pubDate>
</item>
<item>
<title>Recategorized: GATE BT 2024 | Question: 8</title>
<link>https://bt.gateoverflow.in/1005/gate-bt-2024-question-8?show=1005#q1005</link>
<description>&lt;p&gt;$2$-mercaptoethanol breaks the $\_\_\_\_\_\_\_$ covalent bond between light and heavy chains of an immunoglobulin molecule.&lt;/p&gt;

&lt;ol style=&quot;list-style-type:upper-alpha&quot;&gt;
	&lt;li&gt;$\text{C-N}$&amp;nbsp;&lt;/li&gt;
	&lt;li&gt;$\text{N-O}$&lt;/li&gt;
	&lt;li&gt;$\text{S-C}$&lt;/li&gt;
	&lt;li&gt;$\text{S-S}$
	&lt;p&gt;&amp;nbsp;&lt;/p&gt;
	&lt;/li&gt;
&lt;/ol&gt;</description>
<category>Immunology</category>
<guid isPermaLink="true">https://bt.gateoverflow.in/1005/gate-bt-2024-question-8?show=1005#q1005</guid>
<pubDate>Mon, 21 Apr 2025 15:50:13 +0000</pubDate>
</item>
<item>
<title>Recategorized: GATE BT 2023 | Question: 7</title>
<link>https://bt.gateoverflow.in/892/gate-bt-2023-question-7?show=892#q892</link>
<description>&lt;p&gt;Dendritic cells are involved in cross-presentation of antigens. Which of the following protein(s) is(are) required for cross-presentation?&lt;/p&gt;

&lt;p&gt;P. Basic leucine zipper ATF-like transcription factor $3$ (BATF3)&lt;br&gt;
Q. Membrane associated ring-CH-type finger $1$ (MARCH-1)&lt;br&gt;
R. Solute carrier family $10$ member $1$ (SLC10A1)&lt;br&gt;
S. Class II-associated invariant chain peptide (CLIP)&lt;/p&gt;

&lt;ol start=&quot;1&quot; style=&quot;list-style-type:upper-alpha&quot;&gt;
	&lt;li&gt;$\text{P}$ only&lt;/li&gt;
	&lt;li&gt;$\text{P}$ and $\mathrm{R}$ only&lt;/li&gt;
	&lt;li&gt;$\mathrm{P}, \mathrm{Q}$ and $\mathrm{R}$ only&lt;/li&gt;
	&lt;li&gt;$\text{S}$ only&lt;/li&gt;
&lt;/ol&gt;</description>
<category>Immunology</category>
<guid isPermaLink="true">https://bt.gateoverflow.in/892/gate-bt-2023-question-7?show=892#q892</guid>
<pubDate>Mon, 21 Apr 2025 15:46:29 +0000</pubDate>
</item>
<item>
<title>Recategorized: GATE BT 2023 | Question: 6</title>
<link>https://bt.gateoverflow.in/893/gate-bt-2023-question-6?show=893#q893</link>
<description>&lt;p&gt;Which one of the following drugs is &lt;strong&gt;NOT&lt;/strong&gt; an immune checkpoint inhibitor?&lt;/p&gt;

&lt;ol start=&quot;1&quot; style=&quot;list-style-type:upper-alpha&quot;&gt;
	&lt;li&gt;Ipilimumab&lt;/li&gt;
	&lt;li&gt;Pembrolizumab&lt;/li&gt;
	&lt;li&gt;Nivolumab&lt;/li&gt;
	&lt;li&gt;Trastuzumab&lt;/li&gt;
&lt;/ol&gt;</description>
<category>Immunology</category>
<guid isPermaLink="true">https://bt.gateoverflow.in/893/gate-bt-2023-question-6?show=893#q893</guid>
<pubDate>Mon, 21 Apr 2025 15:46:26 +0000</pubDate>
</item>
<item>
<title>Recategorized: GATE BT 2023 | Question: 8</title>
<link>https://bt.gateoverflow.in/891/gate-bt-2023-question-8?show=891#q891</link>
<description>&lt;p&gt;Which one of the following is required for the development of B-cells in the bone marrow?&lt;/p&gt;

&lt;ol style=&quot;list-style-type:upper-alpha&quot;&gt;
	&lt;li&gt;Stromal cells&lt;/li&gt;
	&lt;li&gt;Dendritic cells&lt;/li&gt;
	&lt;li&gt;Kupffer cells&lt;/li&gt;
	&lt;li&gt;NK cells
	&lt;p&gt;&amp;nbsp;&lt;/p&gt;
	&lt;/li&gt;
&lt;/ol&gt;</description>
<category>Immunology</category>
<guid isPermaLink="true">https://bt.gateoverflow.in/891/gate-bt-2023-question-8?show=891#q891</guid>
<pubDate>Mon, 21 Apr 2025 15:46:20 +0000</pubDate>
</item>
<item>
<title>Recategorized: GATE BT 2023 | Question: 26</title>
<link>https://bt.gateoverflow.in/873/gate-bt-2023-question-26?show=873#q873</link>
<description>&lt;p&gt;Match the immune tolerance mechanisms in Group I with their respective outcomes in &lt;strong&gt;Group II&lt;/strong&gt;.&lt;/p&gt;

&lt;table border=&quot;1&quot; cellpadding=&quot;1&quot; style=&quot;width:500px&quot;&gt;
	&lt;tbody&gt;
		&lt;tr&gt;
			&lt;td&gt;&lt;strong&gt;Group I&lt;/strong&gt;&lt;/td&gt;
			&lt;td&gt;&lt;strong&gt;Group II&lt;/strong&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr&gt;
			&lt;td&gt;P. Anergy&lt;/td&gt;
			&lt;td&gt;1. Elimination of activated T-cells&amp;nbsp;after antigen clearance&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr&gt;
			&lt;td&gt;Q. Activation-induced cell death&lt;/td&gt;
			&lt;td&gt;2. Inhibition of auto-reactive T-cells at&amp;nbsp;periphery&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr&gt;
			&lt;td&gt;R. Receptor editing&lt;/td&gt;
			&lt;td&gt;3. Unresponsiveness to antigens due to&amp;nbsp; lack of co-stimulatory molecules&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr&gt;
			&lt;td&gt;S. Regulatory T-cells&lt;/td&gt;
			&lt;td&gt;4. Elimination of auto-reactive B-cells&lt;/td&gt;
		&lt;/tr&gt;
	&lt;/tbody&gt;
&lt;/table&gt;

&lt;p&gt;&amp;nbsp;&lt;/p&gt;

&lt;ol start=&quot;1&quot; style=&quot;list-style-type:upper-alpha&quot;&gt;
	&lt;li&gt;$\text{P-3, Q-1, R-4, S-2}$&lt;/li&gt;
	&lt;li&gt;$\text{P-4, Q-3, R-1, S-2}$&lt;/li&gt;
	&lt;li&gt;$\text{P-3, Q-4, R-2, S-1}$&lt;/li&gt;
	&lt;li&gt;$\text{P-3, Q-2, R-4, S-1}$&lt;/li&gt;
&lt;/ol&gt;</description>
<category>Immunology</category>
<guid isPermaLink="true">https://bt.gateoverflow.in/873/gate-bt-2023-question-26?show=873#q873</guid>
<pubDate>Mon, 21 Apr 2025 15:45:27 +0000</pubDate>
</item>
<item>
<title>Recategorized: GATE BT 2022 | Question: 28</title>
<link>https://bt.gateoverflow.in/802/gate-bt-2022-question-28?show=802#q802</link>
<description>&lt;p&gt;&amp;nbsp;&lt;/p&gt;

&lt;p&gt;Match the cell type (Column I) with its function&amp;nbsp;(Column II).&lt;/p&gt;

&lt;p&gt;$$\begin{array} {lll} \textbf{Column I} &amp;amp; &amp;amp; \textbf{Column II} \\ \text{P. B cells} &amp;amp; &amp;amp; \text{1. Humoral immunity} \\ \text{Q. Neutrophils} &amp;amp; &amp;amp; \text{2.&amp;nbsp;Cytotoxicity}&amp;nbsp;\\ \text{R. T cells} &amp;amp; &amp;amp; \text{3. Histamine-associated allergy}&amp;nbsp;\\ \text{S. Mast cells} &amp;amp; &amp;amp; \text{4. Phagocytosis}\end{array}$$&lt;/p&gt;

&lt;ol start=&quot;1&quot; style=&quot;list-style-type:upper-alpha&quot;&gt;
	&lt;li&gt;$\text{P-1, Q-2, R-3, S-4}$&lt;/li&gt;
	&lt;li&gt;$\text{P-1, Q-4, R-2, S-3}$&amp;nbsp;&lt;/li&gt;
	&lt;li&gt;$\text{P-4, Q-3, R-1, S-2}$&lt;/li&gt;
	&lt;li&gt;$\text{P-4, Q-3, R-2, S-1}$&lt;/li&gt;
&lt;/ol&gt;</description>
<category>Immunology</category>
<guid isPermaLink="true">https://bt.gateoverflow.in/802/gate-bt-2022-question-28?show=802#q802</guid>
<pubDate>Mon, 21 Apr 2025 15:42:38 +0000</pubDate>
</item>
<item>
<title>Recategorized: GATE BT 2021 | Question: 7</title>
<link>https://bt.gateoverflow.in/745/gate-bt-2021-question-7?show=745#q745</link>
<description>&lt;p&gt;Which one of the following statements is $\text{INCORRECT}$ about hybridoma production?&lt;/p&gt;

&lt;ol style=&quot;list-style-type:upper-alpha&quot; type=&quot;A&quot;&gt;
	&lt;li&gt;Hybridoma cella can use hypoxanthine and thymidine&lt;/li&gt;
	&lt;li&gt;$\text{DNA}$ synthesis in myeloma cells&amp;nbsp;is blocked by aminopterin&lt;/li&gt;
	&lt;li&gt;Hybridoma cells are made to produce polyclonal antibodies&lt;/li&gt;
	&lt;li&gt;Polyethylene glycol is used to fuse myeloma cells to $B$-cells&lt;/li&gt;
&lt;/ol&gt;</description>
<category>Immunology</category>
<guid isPermaLink="true">https://bt.gateoverflow.in/745/gate-bt-2021-question-7?show=745#q745</guid>
<pubDate>Mon, 21 Apr 2025 15:40:30 +0000</pubDate>
</item>
<item>
<title>Recategorized: GATE BT 2021 | Question: 30</title>
<link>https://bt.gateoverflow.in/722/gate-bt-2021-question-30?show=722#q722</link>
<description>&lt;p&gt;Match hypersensitivity types in $\text{Group I}$ with their corresponding condition in $\text{Group II}$.&lt;/p&gt;

&lt;p&gt;$$\begin{array}{|l|l|l|l|} \hline &amp;amp; \textbf{Group I} &amp;amp;&amp;amp; \textbf{Group II} \\ \hline P. &amp;amp; \text{Type I} &amp;amp; 1. &amp;amp; \text{Erythroblastosis fetalis} \\ \hline Q. &amp;amp; \text{Type II} &amp;amp; 2. &amp;amp; \text{Host reaction to bee venom} \\ \hline R. &amp;amp; \text{Type III} &amp;amp; 3. &amp;amp; \text{Systemic lupus erythematosus} \\ \hline S. &amp;amp; \text{Type IV} &amp;amp; 4. &amp;amp; \text{Tuberculin reaction} \\ \hline \end{array}$$&lt;/p&gt;

&lt;ol style=&quot;list-style-type:upper-alpha&quot; type=&quot;A&quot;&gt;
	&lt;li&gt;$P-2, Q-3, R-1, S-4$&lt;/li&gt;
	&lt;li&gt;$P-3, Q-1, R-4, S-2$&lt;/li&gt;
	&lt;li&gt;$P-2, Q-3, R-4, S-1$&lt;/li&gt;
	&lt;li&gt;$P-2, Q-1, R-3, S-4$&lt;/li&gt;
&lt;/ol&gt;</description>
<category>Immunology</category>
<guid isPermaLink="true">https://bt.gateoverflow.in/722/gate-bt-2021-question-30?show=722#q722</guid>
<pubDate>Mon, 21 Apr 2025 15:39:55 +0000</pubDate>
</item>
<item>
<title>Recategorized: GATE BT 2021 | Question: 29</title>
<link>https://bt.gateoverflow.in/723/gate-bt-2021-question-29?show=723#q723</link>
<description>&lt;p&gt;Match the autoimmune diseases in $\text{Group I}$ with the corresponding primarily affected organ in $\text{Group II}$.&lt;/p&gt;

&lt;p&gt;$$\begin{array}{|l|l|l|l|} \hline &amp;amp; \textbf{Group I} &amp;amp;&amp;amp; \textbf{Group II} \\ \hline P. &amp;amp; \text{Hashimoto’s disease} &amp;amp; 1. &amp;amp; \text{Brain} \\ \hline Q. &amp;amp; \text{Juvenile diabetes} &amp;amp; 2. &amp;amp; \text{Pancreas} \\ \hline R. &amp;amp; \text{Multiple sclerosis} &amp;amp; 3. &amp;amp; \text{Skeletal muscle} \\ \hline S. &amp;amp; \text{Myasthenia gravis} &amp;amp; 4. &amp;amp; \text{Thyroid} \\ \hline \end{array}$$&lt;/p&gt;

&lt;ol style=&quot;list-style-type:upper-alpha&quot; type=&quot;A&quot;&gt;
	&lt;li&gt;$P-1, Q-2, R-3, S-4$&lt;/li&gt;
	&lt;li&gt;$P-3, Q-1, R-2, S-4$&lt;/li&gt;
	&lt;li&gt;$P-4, Q-2, R-1, S-3$&lt;/li&gt;
	&lt;li&gt;$P-1, Q-2, R-4, S-3$&lt;/li&gt;
&lt;/ol&gt;</description>
<category>Immunology</category>
<guid isPermaLink="true">https://bt.gateoverflow.in/723/gate-bt-2021-question-29?show=723#q723</guid>
<pubDate>Mon, 21 Apr 2025 15:39:52 +0000</pubDate>
</item>
<item>
<title>Recategorized: GATE2020: 28</title>
<link>https://bt.gateoverflow.in/631/gate2020-28?show=631#q631</link>
<description>&lt;p&gt;Which of the following statements about immune response are $CORRECT$?&lt;/p&gt;

&lt;ol start=&quot;16&quot; style=&quot;list-style-type:upper-alpha&quot; type=&quot;A&quot;&gt;
	&lt;li&gt;$T$ cells are activated by antigen-presenting cells&lt;/li&gt;
	&lt;li&gt;Foreign peptides are not presented to helper $T$ cells by Class $II$ $MHC$ proteins&lt;/li&gt;
	&lt;li&gt;Dendritic cells are referred to as professional antigen- presenting cells&lt;/li&gt;
&lt;/ol&gt;

&lt;ol style=&quot;list-style-type:upper-alpha&quot; type=&quot;A&quot;&gt;
	&lt;li&gt;$P$ and $R$&amp;nbsp;only&amp;nbsp;&lt;/li&gt;
	&lt;li&gt;$P$ and $Q$ only&lt;/li&gt;
	&lt;li&gt;$Q$ and $R$ only&amp;nbsp;&lt;/li&gt;
	&lt;li&gt;$P, Q$ and $R$&lt;/li&gt;
&lt;/ol&gt;</description>
<category>Immunology</category>
<guid isPermaLink="true">https://bt.gateoverflow.in/631/gate2020-28?show=631#q631</guid>
<pubDate>Mon, 21 Apr 2025 15:37:59 +0000</pubDate>
</item>
<item>
<title>Recategorized: GATE2020: 4</title>
<link>https://bt.gateoverflow.in/590/gate2020-4?show=590#q590</link>
<description>&lt;p&gt;Which class of antibody is first made by developing $B$ cells inside bone marrow?&lt;/p&gt;

&lt;ol style=&quot;list-style-type:upper-alpha&quot; type=&quot;A&quot;&gt;
	&lt;li&gt;$IgG$&lt;/li&gt;
	&lt;li&gt;$IgE$&lt;/li&gt;
	&lt;li&gt;$IgA$&lt;/li&gt;
	&lt;li&gt;$IgM$&amp;nbsp;&lt;/li&gt;
&lt;/ol&gt;</description>
<category>Immunology</category>
<guid isPermaLink="true">https://bt.gateoverflow.in/590/gate2020-4?show=590#q590</guid>
<pubDate>Mon, 21 Apr 2025 15:36:56 +0000</pubDate>
</item>
<item>
<title>Recategorized: GATE2019: 34</title>
<link>https://bt.gateoverflow.in/675/gate2019-34?show=675#q675</link>
<description>&lt;p&gt;Antibody-producing hybridoma cells are generated by the fusion of a&lt;/p&gt;

&lt;ol style=&quot;list-style-type:upper-alpha&quot; type=&quot;A&quot;&gt;
	&lt;li&gt;$T$ cell with a myeloma cell&lt;/li&gt;
	&lt;li&gt;$B$ cell with a myeloma cell&lt;/li&gt;
	&lt;li&gt;macrophage with a myeloma cell&lt;/li&gt;
	&lt;li&gt;$T$ cell and a $B$ cell&lt;/li&gt;
&lt;/ol&gt;</description>
<category>Immunology</category>
<guid isPermaLink="true">https://bt.gateoverflow.in/675/gate2019-34?show=675#q675</guid>
<pubDate>Mon, 21 Apr 2025 15:35:57 +0000</pubDate>
</item>
<item>
<title>Recategorized: GATE2019: 10</title>
<link>https://bt.gateoverflow.in/519/gate2019-10?show=519#q519</link>
<description>&lt;p&gt;Which one of the following is $NOT$ a part of the human nonspecific defense system?&lt;/p&gt;

&lt;ol style=&quot;list-style-type:upper-alpha&quot; type=&quot;A&quot;&gt;
	&lt;li&gt;Interferon&lt;/li&gt;
	&lt;li&gt;Mucous&lt;/li&gt;
	&lt;li&gt;Saliva&lt;/li&gt;
	&lt;li&gt;Antibody&lt;/li&gt;
&lt;/ol&gt;</description>
<category>Immunology</category>
<guid isPermaLink="true">https://bt.gateoverflow.in/519/gate2019-10?show=519#q519</guid>
<pubDate>Mon, 21 Apr 2025 15:33:51 +0000</pubDate>
</item>
<item>
<title>Retagged: GATE2018-38</title>
<link>https://bt.gateoverflow.in/38/gate2018-38?show=38#q38</link>
<description>&lt;p&gt;A pedigree of an inheritable disease is shown below.&lt;/p&gt;

&lt;p&gt;&lt;img alt=&quot;&quot; src=&quot;https://bt.gateoverflow.in/?qa=blob&amp;amp;qa_blobid=1199359756613080828&quot;&gt;&lt;/p&gt;

&lt;p&gt;What type of inheritance does the disease follow?&lt;/p&gt;

&lt;ol style=&quot;list-style-type:upper-alpha&quot;&gt;
	&lt;li&gt;Autosomal dominant&lt;/li&gt;
	&lt;li&gt;X-linked dominant&lt;/li&gt;
	&lt;li&gt;X-linked recessive&lt;/li&gt;
	&lt;li&gt;Autosomal recessive&lt;/li&gt;
&lt;/ol&gt;</description>
<category>Immunology</category>
<guid isPermaLink="true">https://bt.gateoverflow.in/38/gate2018-38?show=38#q38</guid>
<pubDate>Mon, 21 Apr 2025 15:33:44 +0000</pubDate>
</item>
<item>
<title>Retagged: GATE2018-33</title>
<link>https://bt.gateoverflow.in/33/gate2018-33?show=33#q33</link>
<description>&lt;p&gt;Which one of the following statements is true with regard to processing and presentation of protein antigens?&lt;/p&gt;

&lt;ol style=&quot;list-style-type:upper-alpha&quot;&gt;
	&lt;li&gt;In the class II MHC pathway, protein antigens in the cytosol are processed by proteasomes&lt;/li&gt;
	&lt;li&gt;In the class I MHC pathway, extracellular protein antigens are endocytosed into vesicles and processed&lt;/li&gt;
	&lt;li&gt;In the class I MHC&amp;nbsp;pathway, transporter associated antigen processing (TAP) protein is required for translocating processed peptides generated in the cytosol&lt;/li&gt;
	&lt;li&gt;Invariant chain in endoplasmic reticulum is involved in transport of peptides and loading of class I MHC&lt;/li&gt;
&lt;/ol&gt;</description>
<category>Immunology</category>
<guid isPermaLink="true">https://bt.gateoverflow.in/33/gate2018-33?show=33#q33</guid>
<pubDate>Mon, 21 Apr 2025 15:33:39 +0000</pubDate>
</item>
<item>
<title>Retagged: GATE2018-32</title>
<link>https://bt.gateoverflow.in/32/gate2018-32?show=32#q32</link>
<description>&lt;p&gt;Which one of the combinations of the following statements is true about antibody structure?&lt;/p&gt;

&lt;ol start=&quot;16&quot; style=&quot;list-style-type:upper-alpha&quot; type=&quot;A&quot;&gt;
	&lt;li&gt;Limited proteolysis of rabbit IgG with the enzyme pepsin generates two antigen-binding regions (Fab) and an Fc fragment.&lt;/li&gt;
	&lt;li&gt;Limited proteolysis of rabbit IgG with the enzyme papain generates a single bivalent antigen-binding region F(ab&#039;)$_2$ and peptide fragments.&lt;/li&gt;
	&lt;li&gt;The Fc fragment of IgG can self-associate and crystallize into a lattice.&lt;/li&gt;
	&lt;li&gt;The F(ab&#039;)$_2$ fragment of IgG is composed of both light and heavy chains.&lt;/li&gt;
&lt;/ol&gt;

&lt;ol style=&quot;list-style-type:upper-alpha&quot;&gt;
	&lt;li&gt;P and Q only&lt;/li&gt;
	&lt;li&gt;P and R only&lt;/li&gt;
	&lt;li&gt;R and S only&lt;/li&gt;
	&lt;li&gt;Q and S only&lt;/li&gt;
&lt;/ol&gt;</description>
<category>Immunology</category>
<guid isPermaLink="true">https://bt.gateoverflow.in/32/gate2018-32?show=32#q32</guid>
<pubDate>Mon, 21 Apr 2025 15:33:37 +0000</pubDate>
</item>
<item>
<title>Retagged: GATE2018-30</title>
<link>https://bt.gateoverflow.in/30/gate2018-30?show=30#q30</link>
<description>&lt;p&gt;Which one of the following amino acids is catalyzed by activated macrophages to produce reactive nitrogen species?&lt;/p&gt;

&lt;ol style=&quot;list-style-type:upper-alpha&quot;&gt;
	&lt;li&gt;Arginine&lt;/li&gt;
	&lt;li&gt;Asparagine&lt;/li&gt;
	&lt;li&gt;Cysteine&lt;/li&gt;
	&lt;li&gt;Histidine&lt;/li&gt;
&lt;/ol&gt;</description>
<category>Immunology</category>
<guid isPermaLink="true">https://bt.gateoverflow.in/30/gate2018-30?show=30#q30</guid>
<pubDate>Mon, 21 Apr 2025 15:33:35 +0000</pubDate>
</item>
<item>
<title>Retagged: GATE2018-27</title>
<link>https://bt.gateoverflow.in/27/gate2018-27?show=27#q27</link>
<description>&lt;p&gt;Which of the following cytokines are endogenous pylogens?&lt;/p&gt;

&lt;ol start=&quot;16&quot; style=&quot;list-style-type:upper-alpha&quot; type=&quot;A&quot;&gt;
	&lt;li&gt;Tumor necrosis factor-$\alpha$&lt;/li&gt;
	&lt;li&gt;Interleukin-$1$&lt;/li&gt;
	&lt;li&gt;Transforming growth factor-$\beta$&lt;/li&gt;
	&lt;li&gt;Interleukin-$10$&lt;/li&gt;
&lt;/ol&gt;

&lt;ol style=&quot;list-style-type:upper-alpha&quot;&gt;
	&lt;li&gt;P and Q only&lt;/li&gt;
	&lt;li&gt;P and R only&lt;/li&gt;
	&lt;li&gt;R and S only&lt;/li&gt;
	&lt;li&gt;Q and S only&lt;/li&gt;
&lt;/ol&gt;</description>
<category>Immunology</category>
<guid isPermaLink="true">https://bt.gateoverflow.in/27/gate2018-27?show=27#q27</guid>
<pubDate>Mon, 21 Apr 2025 15:33:31 +0000</pubDate>
</item>
<item>
<title>Recategorized: GATE BT 2017 | Question: 7</title>
<link>https://bt.gateoverflow.in/384/gate-bt-2017-question-7?show=384#q384</link>
<description>&lt;p&gt;Which one of the following mechanisms is used by human pathogens to evade host immune responses?&lt;/p&gt;

&lt;ol style=&quot;list-style-type:upper-alpha&quot; type=&quot;A&quot;&gt;
	&lt;li&gt;Somatic hypermutation&lt;/li&gt;
	&lt;li&gt;Antibody production&lt;/li&gt;
	&lt;li&gt;Antigenic variation&lt;/li&gt;
	&lt;li&gt;Complement activation&lt;/li&gt;
&lt;/ol&gt;</description>
<category>Immunology</category>
<guid isPermaLink="true">https://bt.gateoverflow.in/384/gate-bt-2017-question-7?show=384#q384</guid>
<pubDate>Mon, 21 Apr 2025 15:33:21 +0000</pubDate>
</item>
<item>
<title>Recategorized: GATE BT 2017 | Question: 13</title>
<link>https://bt.gateoverflow.in/378/gate-bt-2017-question-13?show=378#q378</link>
<description>&lt;p&gt;Macrophages eliminate pathogenic bacteria upon activation by&lt;/p&gt;

&lt;ol style=&quot;list-style-type:upper-alpha&quot; type=&quot;A&quot;&gt;
	&lt;li&gt;NK cells&lt;/li&gt;
	&lt;li&gt;basophils&lt;/li&gt;
	&lt;li&gt;CD$4+$ T cells&lt;/li&gt;
	&lt;li&gt;plasma cells&lt;/li&gt;
&lt;/ol&gt;</description>
<category>Immunology</category>
<guid isPermaLink="true">https://bt.gateoverflow.in/378/gate-bt-2017-question-13?show=378#q378</guid>
<pubDate>Mon, 21 Apr 2025 15:33:01 +0000</pubDate>
</item>
<item>
<title>Recategorized: GATE BT 2017 | Question: 12</title>
<link>https://bt.gateoverflow.in/379/gate-bt-2017-question-12?show=379#q379</link>
<description>&lt;p&gt;Enzyme-linked immunosorbent assay (ELISA) is used for&lt;/p&gt;

&lt;ol style=&quot;list-style-type:upper-alpha&quot; type=&quot;A&quot;&gt;
	&lt;li&gt;quantifying antibody levels in blood&lt;/li&gt;
	&lt;li&gt;determining the molecular weight of an antigen&lt;/li&gt;
	&lt;li&gt;purifying proteins from biological ﬂuids&lt;/li&gt;
	&lt;li&gt;determining the molecular weight of an antibody&lt;/li&gt;
&lt;/ol&gt;</description>
<category>Immunology</category>
<guid isPermaLink="true">https://bt.gateoverflow.in/379/gate-bt-2017-question-12?show=379#q379</guid>
<pubDate>Mon, 21 Apr 2025 15:32:58 +0000</pubDate>
</item>
<item>
<title>Recategorized: GATE BT 2017 | Question: 40</title>
<link>https://bt.gateoverflow.in/351/gate-bt-2017-question-40?show=351#q351</link>
<description>&lt;p&gt;An immunocompetent person becomes infected with a pathogenic strain of bacteria. Which one of the following graphs correctly depicts bacterial load in this person over time?&lt;/p&gt;

&lt;ol style=&quot;list-style-type:upper-alpha&quot; type=&quot;A&quot;&gt;
	&lt;li&gt;&lt;img alt=&quot;&quot; src=&quot;https://bt.gateoverflow.in/?qa=blob&amp;amp;qa_blobid=11707592057798593979&quot;&gt;&lt;/li&gt;
	&lt;li&gt;&lt;img alt=&quot;&quot; src=&quot;https://bt.gateoverflow.in/?qa=blob&amp;amp;qa_blobid=12034652062672428327&quot;&gt;&lt;/li&gt;
	&lt;li&gt;&lt;img alt=&quot;&quot; src=&quot;https://bt.gateoverflow.in/?qa=blob&amp;amp;qa_blobid=4134040089046507682&quot;&gt;&lt;/li&gt;
	&lt;li&gt;&lt;img alt=&quot;&quot; src=&quot;https://bt.gateoverflow.in/?qa=blob&amp;amp;qa_blobid=14805839479784921655&quot;&gt;&lt;/li&gt;
&lt;/ol&gt;</description>
<category>Immunology</category>
<guid isPermaLink="true">https://bt.gateoverflow.in/351/gate-bt-2017-question-40?show=351#q351</guid>
<pubDate>Mon, 21 Apr 2025 15:31:39 +0000</pubDate>
</item>
<item>
<title>Recategorized: GATE BT 2017 | Question: 55</title>
<link>https://bt.gateoverflow.in/336/gate-bt-2017-question-55?show=336#q336</link>
<description>&lt;p&gt;Which of the following conditions promote the development of human autoimmune disorders?&lt;/p&gt;

&lt;ol start=&quot;16&quot; style=&quot;list-style-type:upper-alpha&quot; type=&quot;A&quot;&gt;
	&lt;li&gt;Inability to eliminate self-reactive lymphocytes&lt;/li&gt;
	&lt;li&gt;Generation of auto-antibodies&lt;/li&gt;
	&lt;li&gt;Ability to eliminate self-reactive T-cells&lt;/li&gt;
	&lt;li&gt;Induction of regulatory T-cells in the thymus&lt;/li&gt;
&lt;/ol&gt;

&lt;ol style=&quot;list-style-type:upper-alpha&quot; type=&quot;A&quot;&gt;
	&lt;li&gt;P,R&lt;/li&gt;
	&lt;li&gt;Q,S&lt;/li&gt;
	&lt;li&gt;P,Q&lt;/li&gt;
	&lt;li&gt;R,S&lt;/li&gt;
&lt;/ol&gt;</description>
<category>Immunology</category>
<guid isPermaLink="true">https://bt.gateoverflow.in/336/gate-bt-2017-question-55?show=336#q336</guid>
<pubDate>Mon, 21 Apr 2025 15:31:04 +0000</pubDate>
</item>
<item>
<title>Recategorized: GATE2016-11</title>
<link>https://bt.gateoverflow.in/435/gate2016-11?show=435#q435</link>
<description>&lt;p&gt;Junctional diversity of antibody molecules results from&lt;/p&gt;

&lt;ol style=&quot;list-style-type:upper-alpha&quot;&gt;
	&lt;li&gt;the addition of switch region nucleotides&lt;/li&gt;
	&lt;li&gt;the addition of N and P nucleotides&lt;/li&gt;
	&lt;li&gt;the joining of V, D and J segments&lt;/li&gt;
	&lt;li&gt;mutations in complementarity-determining regions&lt;/li&gt;
&lt;/ol&gt;</description>
<category>Immunology</category>
<guid isPermaLink="true">https://bt.gateoverflow.in/435/gate2016-11?show=435#q435</guid>
<pubDate>Mon, 21 Apr 2025 15:29:52 +0000</pubDate>
</item>
<item>
<title>Recategorized: GATE2016-37</title>
<link>https://bt.gateoverflow.in/409/gate2016-37?show=409#q409</link>
<description>&lt;p&gt;Find the INCORRECT combination&lt;/p&gt;

&lt;ol style=&quot;list-style-type:upper-alpha&quot;&gt;
	&lt;li&gt;Surface immunoglobulins – B cell antigen receptor&lt;/li&gt;
	&lt;li&gt;Affinity maturation - isotype switching&lt;/li&gt;
	&lt;li&gt;Fc region of antibodies – binding to complement proteins&lt;/li&gt;
	&lt;li&gt;Spleen, the secondary lymphoid organ – no connection with the lymphatic system&lt;/li&gt;
&lt;/ol&gt;</description>
<category>Immunology</category>
<guid isPermaLink="true">https://bt.gateoverflow.in/409/gate2016-37?show=409#q409</guid>
<pubDate>Mon, 21 Apr 2025 15:29:22 +0000</pubDate>
</item>
<item>
<title>Recategorized: GATE2016-38</title>
<link>https://bt.gateoverflow.in/408/gate2016-38?show=408#q408</link>
<description>&lt;p&gt;Which of the following statement(s) is/are CORRECT for antigen activated effector T cells?&lt;/p&gt;

&lt;ol start=&quot;16&quot; style=&quot;list-style-type:upper-alpha&quot; type=&quot;A&quot;&gt;
	&lt;li&gt;$CD4^+$ cells make contact with macrophages and stimulate their microbicidal activity.&lt;/li&gt;
	&lt;li&gt;$CD4^+$ cells make contact with B cells and stimulate them to differentiate into plasma cells.&lt;/li&gt;
	&lt;li&gt;$CD8^+$ cells make contact with B cells and stimulate them to differentiate into plasma cells.&lt;/li&gt;
	&lt;li&gt;$CD8^+$ cells make contact with virus infected cells and kill them&lt;/li&gt;
&lt;/ol&gt;

&lt;ol style=&quot;list-style-type:upper-alpha&quot;&gt;
	&lt;li&gt;$Q$ only&lt;/li&gt;
	&lt;li&gt;$Q$ and $S$ only&lt;/li&gt;
	&lt;li&gt;$P, Q$ and $S$ only&lt;/li&gt;
	&lt;li&gt;$P, Q, R$ and $S$&lt;/li&gt;
&lt;/ol&gt;</description>
<category>Immunology</category>
<guid isPermaLink="true">https://bt.gateoverflow.in/408/gate2016-38?show=408#q408</guid>
<pubDate>Mon, 21 Apr 2025 15:28:47 +0000</pubDate>
</item>
<item>
<title>Recategorized: GATE BT 2015 | Question: 11</title>
<link>https://bt.gateoverflow.in/315/gate-bt-2015-question-11?show=315#q315</link>
<description>&lt;p&gt;Which one of the following complement proteins is the initiator of the membrane attack complex&lt;/p&gt;

&lt;ol style=&quot;list-style-type:upper-alpha&quot; type=&quot;A&quot;&gt;
	&lt;li&gt;$C3a$&lt;/li&gt;
	&lt;li&gt;$C3b$&lt;/li&gt;
	&lt;li&gt;$C5a$&lt;/li&gt;
	&lt;li&gt;$C5b$&lt;/li&gt;
&lt;/ol&gt;</description>
<category>Immunology</category>
<guid isPermaLink="true">https://bt.gateoverflow.in/315/gate-bt-2015-question-11?show=315#q315</guid>
<pubDate>Mon, 21 Apr 2025 15:28:07 +0000</pubDate>
</item>
<item>
<title>Recategorized: GATE BT 2015 | Question: 17</title>
<link>https://bt.gateoverflow.in/309/gate-bt-2015-question-17?show=309#q309</link>
<description>&lt;p&gt;ABO blood group antigens in humans are differentiated from each other on the basis of&lt;/p&gt;

&lt;ol style=&quot;list-style-type:upper-alpha&quot;&gt;
	&lt;li&gt;sialic acid&lt;/li&gt;
	&lt;li&gt;lipids&lt;/li&gt;
	&lt;li&gt;spectrin&lt;/li&gt;
	&lt;li&gt;glycoproteins&lt;/li&gt;
&lt;/ol&gt;</description>
<category>Immunology</category>
<guid isPermaLink="true">https://bt.gateoverflow.in/309/gate-bt-2015-question-17?show=309#q309</guid>
<pubDate>Mon, 21 Apr 2025 15:28:01 +0000</pubDate>
</item>
<item>
<title>Recategorized: GATE BT 2015 | Question: 16</title>
<link>https://bt.gateoverflow.in/310/gate-bt-2015-question-16?show=310#q310</link>
<description>&lt;p&gt;Anergy refers to&lt;/p&gt;

&lt;ol style=&quot;list-style-type:upper-alpha&quot; type=&quot;A&quot;&gt;
	&lt;li&gt;nitochondrial dysfunction&lt;/li&gt;
	&lt;li&gt;allergy to environmental antigens&lt;/li&gt;
	&lt;li&gt;&amp;nbsp;unresponsiveness to antigens&lt;/li&gt;
	&lt;li&gt;a state of no energy&lt;/li&gt;
&lt;/ol&gt;</description>
<category>Immunology</category>
<guid isPermaLink="true">https://bt.gateoverflow.in/310/gate-bt-2015-question-16?show=310#q310</guid>
<pubDate>Mon, 21 Apr 2025 15:27:59 +0000</pubDate>
</item>
<item>
<title>Recategorized: GATE BT 2015 | Question: 14</title>
<link>https://bt.gateoverflow.in/312/gate-bt-2015-question-14?show=312#q312</link>
<description>&lt;p&gt;Based on the heavy chain,&amp;nbsp;which one of the following antibodies has multiple subtypes?&lt;/p&gt;

&lt;ol style=&quot;list-style-type:upper-alpha&quot;&gt;
	&lt;li&gt;IgM&lt;/li&gt;
	&lt;li&gt;IgD&lt;/li&gt;
	&lt;li&gt;IgE&lt;/li&gt;
	&lt;li&gt;IgG&lt;/li&gt;
&lt;/ol&gt;</description>
<category>Immunology</category>
<guid isPermaLink="true">https://bt.gateoverflow.in/312/gate-bt-2015-question-14?show=312#q312</guid>
<pubDate>Mon, 21 Apr 2025 15:27:53 +0000</pubDate>
</item>
<item>
<title>Recategorized: GATE BT 2015 | Question: 24</title>
<link>https://bt.gateoverflow.in/302/gate-bt-2015-question-24?show=302#q302</link>
<description>&lt;p&gt;Production of monoclonal antibodies by hybridoma technology requires&lt;/p&gt;

&lt;ol style=&quot;list-style-type:upper-alpha&quot;&gt;
	&lt;li&gt;splenocytes&lt;/li&gt;
	&lt;li&gt;osteocytes&lt;/li&gt;
	&lt;li&gt;hepatocytes&lt;/li&gt;
	&lt;li&gt;thymocytes&lt;/li&gt;
&lt;/ol&gt;</description>
<category>Immunology</category>
<guid isPermaLink="true">https://bt.gateoverflow.in/302/gate-bt-2015-question-24?show=302#q302</guid>
<pubDate>Mon, 21 Apr 2025 15:27:37 +0000</pubDate>
</item>
<item>
<title>Recategorized: GATE BT 2015 | Question: 43</title>
<link>https://bt.gateoverflow.in/283/gate-bt-2015-question-43?show=283#q283</link>
<description>&lt;p&gt;Match the cells in $\text{Group I}$ with their corresponding entries in $\text{Group II}$&lt;/p&gt;

&lt;p&gt;$\begin{array}{|l|l|l|l|} \hline &amp;amp; \textbf{Group I} &amp;amp;&amp;amp; \textbf{Group II} \\ \hline P. &amp;amp; \text{Mast cells} &amp;amp; 1. &amp;amp; \text{Activation of the complement pathway} \\ \hline Q. &amp;amp; \text{Natural killer cells} &amp;amp; 2. &amp;amp; \text{Expression of CD56} \\ \hline R. &amp;amp; \text{Neutrophils} &amp;amp; 3. &amp;amp; \text{Contains azurophilic granules} \\ \hline S. &amp;amp; \text{Dentritic cells} &amp;amp; 4. &amp;amp; \text{Defense against helminthic infection} \\ \hline &amp;amp;&amp;amp; 5. &amp;amp; \text{Production of antibodies specific to bacteria} \\ \hline &amp;amp;&amp;amp; 6. &amp;amp; \text{Contains long menbranous projections} \\ \hline \end{array}$&lt;/p&gt;

&lt;ol style=&quot;list-style-type:upper-alpha&quot; type=&quot;A&quot;&gt;
	&lt;li&gt;$\text{P-4, Q-2, R-3, S-5}$&lt;/li&gt;
	&lt;li&gt;$\text{P-4, Q-2, R-3, S-6}$&lt;/li&gt;
	&lt;li&gt;$\text{P-3, Q-1, R-2, S-5}$&lt;/li&gt;
	&lt;li&gt;$\text{P-3, Q-1, R-2, S-6}$&lt;/li&gt;
&lt;/ol&gt;</description>
<category>Immunology</category>
<guid isPermaLink="true">https://bt.gateoverflow.in/283/gate-bt-2015-question-43?show=283#q283</guid>
<pubDate>Mon, 21 Apr 2025 15:26:43 +0000</pubDate>
</item>
<item>
<title>Recategorized: GATE BT 2015 | Question: 59</title>
<link>https://bt.gateoverflow.in/267/gate-bt-2015-question-59?show=267#q267</link>
<description>&lt;p&gt;Three distinct antigens $X, Y$ and $Z$ were used to raise antibodies. Antigen $Z$ was injected in a mouse on day zero followed by the administration of antigens $X$ and $Y$ on day $28$. A second injection of antigen $X$ was administered on day $70$. The antibody titers were monitored in the serum every day and the results are shown below:&lt;/p&gt;

&lt;p&gt;&lt;img alt=&quot;&quot; src=&quot;https://bt.gateoverflow.in/?qa=blob&amp;amp;qa_blobid=5437678516073813242&quot;&gt;&lt;/p&gt;

&lt;p&gt;Which one of the following statements regarding the antibody titers in the serum is INCORRECT?&lt;/p&gt;

&lt;ol style=&quot;list-style-type:upper-alpha&quot; type=&quot;A&quot;&gt;
	&lt;li&gt;$Z$-specic IgG Will be high on day $14$&lt;/li&gt;
	&lt;li&gt;$X$-specic antibody titer will be high on day $84$&lt;/li&gt;
	&lt;li&gt;$X$-specific IgG will be high on day $42$&lt;/li&gt;
	&lt;li&gt;$Y$-specific IgG will be high on day $84$&lt;/li&gt;
&lt;/ol&gt;</description>
<category>Immunology</category>
<guid isPermaLink="true">https://bt.gateoverflow.in/267/gate-bt-2015-question-59?show=267#q267</guid>
<pubDate>Mon, 21 Apr 2025 15:26:12 +0000</pubDate>
</item>
<item>
<title>Retagged: GATE2014-21</title>
<link>https://bt.gateoverflow.in/230/gate2014-21?show=230#q230</link>
<description>&lt;p&gt;Reactions between antibodies and antigens that are detected by precipitate formation in an agar gel are referred as&lt;/p&gt;

&lt;ol style=&quot;list-style-type:upper-alpha&quot;&gt;
	&lt;li&gt;immunoprecipitation assay&lt;/li&gt;
	&lt;li&gt;immunodiffusion assay&lt;/li&gt;
	&lt;li&gt;immunoaggregation assay&lt;/li&gt;
	&lt;li&gt;immunofixation assay&lt;/li&gt;
&lt;/ol&gt;</description>
<category>Immunology</category>
<guid isPermaLink="true">https://bt.gateoverflow.in/230/gate2014-21?show=230#q230</guid>
<pubDate>Mon, 21 Apr 2025 15:24:52 +0000</pubDate>
</item>
<item>
<title>Recategorized: GATE2014-46</title>
<link>https://bt.gateoverflow.in/205/gate2014-46?show=205#q205</link>
<description>&lt;p&gt;Match the immunoglobulin class in $\text{Group I}$ with its properties in $\text{Group II}$&lt;/p&gt;

&lt;p&gt;$\begin{array}{|l|l|l|l|} \hline &amp;amp; \textbf{Group I} &amp;amp;&amp;amp; \textbf{Group II} \\ \hline P. &amp;amp; \text{IgG} &amp;amp; 1. &amp;amp; \text{Major antibody in external sections} \\ &amp;amp;&amp;amp;&amp;amp; \text{such as bronchial mucus} \\ \hline Q. &amp;amp; \text{IgA} &amp;amp; 2. &amp;amp; \text{Protects against parasites} \\ \hline R. &amp;amp; \text{IgE} &amp;amp; 3. &amp;amp; \text{Antibody that appears first in serum} \\ &amp;amp;&amp;amp;&amp;amp; \text{after exposure to an antigen} \\ \hline S. &amp;amp; \text{IgM} &amp;amp; 4. &amp;amp; \text{Antobody present in highest} \\ &amp;amp;&amp;amp;&amp;amp; \text{concentration in serum} \\ \hline \end{array}$&lt;/p&gt;

&lt;ol style=&quot;list-style-type:upper-alpha&quot;&gt;
	&lt;li&gt;$\text{P-4, Q-1, R-2, S-3}$&lt;/li&gt;
	&lt;li&gt;$\text{P-3, Q-2, R-1, S-4}$&lt;/li&gt;
	&lt;li&gt;$\text{P-4, Q-3, R-1, S-2}$&lt;/li&gt;
	&lt;li&gt;$\text{P-1, Q-4, R-3, S-2}$&lt;/li&gt;
&lt;/ol&gt;</description>
<category>Immunology</category>
<guid isPermaLink="true">https://bt.gateoverflow.in/205/gate2014-46?show=205#q205</guid>
<pubDate>Mon, 21 Apr 2025 15:24:03 +0000</pubDate>
</item>
<item>
<title>Retagged: GATE BT 2013 | Question: 6</title>
<link>https://bt.gateoverflow.in/136/gate-bt-2013-question-6?show=136#q136</link>
<description>&lt;p&gt;The role of an adjuvant isto&lt;/p&gt;

&lt;ol style=&quot;list-style-type:upper-alpha&quot;&gt;
	&lt;li&gt;prolong the persistence of antigen&lt;/li&gt;
	&lt;li&gt;cross link the antigen&lt;/li&gt;
	&lt;li&gt;increase the size of antigen&lt;/li&gt;
	&lt;li&gt;avoid inflammation&lt;/li&gt;
&lt;/ol&gt;</description>
<category>Immunology</category>
<guid isPermaLink="true">https://bt.gateoverflow.in/136/gate-bt-2013-question-6?show=136#q136</guid>
<pubDate>Mon, 21 Apr 2025 15:21:50 +0000</pubDate>
</item>
<item>
<title>Retagged: GATE BT 2013 | Question: 4</title>
<link>https://bt.gateoverflow.in/134/gate-bt-2013-question-4?show=134#q134</link>
<description>&lt;p&gt;The first humanized monoclonal antibody approved for the treatment of breast canceris&lt;/p&gt;

&lt;ol style=&quot;list-style-type:upper-alpha&quot;&gt;
	&lt;li&gt;Rituximab&lt;/li&gt;
	&lt;li&gt;Cetuximab&lt;/li&gt;
	&lt;li&gt;Bevacizumab&lt;/li&gt;
	&lt;li&gt;Herceptin&lt;/li&gt;
&lt;/ol&gt;</description>
<category>Immunology</category>
<guid isPermaLink="true">https://bt.gateoverflow.in/134/gate-bt-2013-question-4?show=134#q134</guid>
<pubDate>Mon, 21 Apr 2025 15:21:46 +0000</pubDate>
</item>
<item>
<title>Retagged: GATE BT 2013 | Question: 3</title>
<link>https://bt.gateoverflow.in/133/gate-bt-2013-question-3?show=133#q133</link>
<description>&lt;p&gt;Protein A, which has strong affinity to $F_C$ region of immunoglobulin,&amp;nbsp;is extracted from&lt;/p&gt;

&lt;ol start=&quot;1&quot; style=&quot;list-style-type:upper-alpha&quot;&gt;
	&lt;li&gt;$\text{Saccharomyces&amp;nbsp;cerevisiae}$&lt;/li&gt;
	&lt;li&gt;$\text{Staphylococcus&amp;nbsp;aureus}$&lt;/li&gt;
	&lt;li&gt;$\text{Streptococcus&amp;nbsp;pyogenes}$&lt;/li&gt;
	&lt;li&gt;$\text{Streptococcus&amp;nbsp;sanguis}$&lt;/li&gt;
&lt;/ol&gt;</description>
<category>Immunology</category>
<guid isPermaLink="true">https://bt.gateoverflow.in/133/gate-bt-2013-question-3?show=133#q133</guid>
<pubDate>Mon, 21 Apr 2025 15:21:43 +0000</pubDate>
</item>
<item>
<title>Recategorized: GATE BT 2012 | Question: 9</title>
<link>https://bt.gateoverflow.in/74/gate-bt-2012-question-9?show=74#q74</link>
<description>&lt;p&gt;Heat inactivation of serum is done to inactivate&lt;/p&gt;

&lt;ol style=&quot;list-style-type:upper-alpha&quot;&gt;
	&lt;li&gt;prions&lt;/li&gt;
	&lt;li&gt;mycoplasma&lt;/li&gt;
	&lt;li&gt;complement&lt;/li&gt;
	&lt;li&gt;pathogenic bacteria&lt;/li&gt;
&lt;/ol&gt;</description>
<category>Immunology</category>
<guid isPermaLink="true">https://bt.gateoverflow.in/74/gate-bt-2012-question-9?show=74#q74</guid>
<pubDate>Mon, 21 Apr 2025 15:19:29 +0000</pubDate>
</item>
<item>
<title>Recategorized: GATE BT 2012 | Question: 8</title>
<link>https://bt.gateoverflow.in/73/gate-bt-2012-question-8?show=73#q73</link>
<description>&lt;p&gt;Nude mice refers to&lt;/p&gt;

&lt;ol style=&quot;list-style-type:upper-alpha&quot;&gt;
	&lt;li&gt;mice without skin&lt;/li&gt;
	&lt;li&gt;mice without thymus&lt;/li&gt;
	&lt;li&gt;knockout mice&lt;/li&gt;
	&lt;li&gt;transgenic mice&lt;/li&gt;
&lt;/ol&gt;</description>
<category>Immunology</category>
<guid isPermaLink="true">https://bt.gateoverflow.in/73/gate-bt-2012-question-8?show=73#q73</guid>
<pubDate>Mon, 21 Apr 2025 15:19:26 +0000</pubDate>
</item>
<item>
<title>Recategorized: GATE BT 2012 | Question: 6</title>
<link>https://bt.gateoverflow.in/71/gate-bt-2012-question-6?show=71#q71</link>
<description>&lt;p&gt;A humanized antibody is one in which the&lt;/p&gt;

&lt;ol style=&quot;list-style-type:upper-alpha&quot;&gt;
	&lt;li&gt;heavy and light chains are from human&lt;/li&gt;
	&lt;li&gt;heavy&amp;nbsp;chain is from human and light chain is from mouse&lt;/li&gt;
	&lt;li&gt;light chain is from human and heavy&amp;nbsp;chain is from mouse&lt;/li&gt;
	&lt;li&gt;CDRs are from mouse, and the rest is from human&lt;/li&gt;
&lt;/ol&gt;</description>
<category>Immunology</category>
<guid isPermaLink="true">https://bt.gateoverflow.in/71/gate-bt-2012-question-6?show=71#q71</guid>
<pubDate>Mon, 21 Apr 2025 15:19:20 +0000</pubDate>
</item>
<item>
<title>Recategorized: GATE BT 2012 | Question: 5</title>
<link>https://bt.gateoverflow.in/70/gate-bt-2012-question-5?show=70#q70</link>
<description>&lt;p&gt;B-lymphocytes originate from the bone marrow whereas T-lymphocytes originate from&lt;/p&gt;

&lt;ol style=&quot;list-style-type:upper-alpha&quot;&gt;
	&lt;li&gt;thymus&lt;/li&gt;
	&lt;li&gt;bone marrow&lt;/li&gt;
	&lt;li&gt;spleen&lt;/li&gt;
	&lt;li&gt;liver&lt;/li&gt;
&lt;/ol&gt;</description>
<category>Immunology</category>
<guid isPermaLink="true">https://bt.gateoverflow.in/70/gate-bt-2012-question-5?show=70#q70</guid>
<pubDate>Mon, 21 Apr 2025 15:19:18 +0000</pubDate>
</item>
<item>
<title>Recategorized: GATE BT 2012 | Question: 4</title>
<link>https://bt.gateoverflow.in/69/gate-bt-2012-question-4?show=69#q69</link>
<description>&lt;p&gt;Identification of blood groups involves&lt;/p&gt;

&lt;ol style=&quot;list-style-type:upper-alpha&quot;&gt;
	&lt;li&gt;precipitation&lt;/li&gt;
	&lt;li&gt;neutralization&lt;/li&gt;
	&lt;li&gt;opsonization&lt;/li&gt;
	&lt;li&gt;agglutination&lt;/li&gt;
&lt;/ol&gt;</description>
<category>Immunology</category>
<guid isPermaLink="true">https://bt.gateoverflow.in/69/gate-bt-2012-question-4?show=69#q69</guid>
<pubDate>Mon, 21 Apr 2025 15:19:15 +0000</pubDate>
</item>
<item>
<title>Recategorized: GATE BT 2012 | Question: 3</title>
<link>https://bt.gateoverflow.in/68/gate-bt-2012-question-3?show=68#q68</link>
<description>&lt;p&gt;Idiotypic determinants of an antibody are associated with the&lt;/p&gt;

&lt;ol style=&quot;list-style-type:upper-alpha&quot;&gt;
	&lt;li&gt;constant region of the heavy&amp;nbsp;chains&lt;/li&gt;
	&lt;li&gt;constant region of the light chains&lt;/li&gt;
	&lt;li&gt;variable region&lt;/li&gt;
	&lt;li&gt;constant regions of light and heavy&amp;nbsp;chains&lt;/li&gt;
&lt;/ol&gt;</description>
<category>Immunology</category>
<guid isPermaLink="true">https://bt.gateoverflow.in/68/gate-bt-2012-question-3?show=68#q68</guid>
<pubDate>Mon, 21 Apr 2025 15:19:12 +0000</pubDate>
</item>
<item>
<title>Recategorized: GATE2018-11</title>
<link>https://bt.gateoverflow.in/11/gate2018-11?show=11#q11</link>
<description>&lt;p&gt;Which one of the following is NOT a principal component of innate immunity?&lt;/p&gt;

&lt;ol style=&quot;list-style-type:upper-alpha&quot;&gt;
	&lt;li&gt;Mucosal epithelia&lt;/li&gt;
	&lt;li&gt;Dendritic cells&lt;/li&gt;
	&lt;li&gt;Complement system&lt;/li&gt;
	&lt;li&gt;Memory B-cells&lt;/li&gt;
&lt;/ol&gt;</description>
<category>Immunology</category>
<guid isPermaLink="true">https://bt.gateoverflow.in/11/gate2018-11?show=11#q11</guid>
<pubDate>Wed, 17 Mar 2021 14:12:40 +0000</pubDate>
</item>
<item>
<title>Edited: GATE BT 2013 | Question: 51</title>
<link>https://bt.gateoverflow.in/181/gate-bt-2013-question-51?show=181#q181</link>
<description>&lt;p&gt;Which one of the receptors has the highest affinity for the ligand?&lt;/p&gt;

&lt;ol style=&quot;list-style-type:upper-alpha&quot;&gt;
	&lt;li&gt;$R1$&lt;/li&gt;
	&lt;li&gt;$R2$&lt;/li&gt;
	&lt;li&gt;$R3$&lt;/li&gt;
	&lt;li&gt;$R4$&lt;/li&gt;
&lt;/ol&gt;</description>
<category>Immunology</category>
<guid isPermaLink="true">https://bt.gateoverflow.in/181/gate-bt-2013-question-51?show=181#q181</guid>
<pubDate>Sat, 07 Nov 2020 07:20:40 +0000</pubDate>
</item>
</channel>
</rss>